Amgad Albohy

Title : Tackling mycobacterium tuberculosis resistance with tailored isatin-pyrimidine hybrids enoyl acyl carrier protein reductase (Inha)

Abstract:

Tuberculosis is a worldwide problem that imposes a burden on the economy due to the continuous development of resistant strains. The development of new antitubercular drugs is a need and can be achieved through the inhibition of druggable targets. Mycobacterium tuberculosis enoyl acyl carrier protein (ACP) reductase (InhA) is an important enzyme for TB survival. In the presentation, we will show the synthesis of isatin derivatives that could control TB through the inhibition of this enzyme. Compound 4m showed IC₅₀ similar to isoniazid but is also effective against resistant TB strains. Molecular docking studies suggest that this compound binds through the use of a relatively unexplored hydrophobic pocket in the active site. This study paves the way for the design and synthesis of novel antitubercular drugs.

Biography:

Dr. Amgad Albohy is an associate professor of Pharmaceutical Chemistry, at the Faculty of Pharmacy, BUE. He received his Ph.D. in Chemical Biology from the University of Alberta, Canada, and was working at the Alberta Glycomics Centre. He was trained at both Friedrich Schiller University in Germany and the Complex Carbohydrate Research Center (CCRC), University of Georgia, USA. Dr. Albohy is interested in the area of molecular modeling with a special focus on molecular docking and dynamics. His research focuses on the design of selective inhibitors among closely related isozymes.